The mutations reported in gefitinib-sensitive NSCLC were located in the TK domain encoded by exons 18–21, and have been shown to increase growth factor signalling and confer susceptibility to gefitinib in vitro (Lynch et al, 2004; Paez et al, 2004). The gene discussed is TKT; the disease is non-small cell lung carcinoma.